MindImmune, a drug discovery firm at the University of Rhode Island, is poised to move into clinical trials, pioneering a breakthrough approach to preventing Alzheimer’s disease, focused on blocking aberrant immune cells in the blood from entering the brain
This item is available in full to subscribers.
If you're a print subscriber, but do not yet have an online account, click here to create one.
Click here to see your options for becoming a subscriber.
If you made a voluntary contribution in 2021-2022, but do not yet have an online account, click here to create one at no additional charge. VIP Digital Access includes access to all websites and online content.
Other items that may interest you
We have noticed you are using an ad blocking plugin in your browser.
The revenue we receive from our advertisers helps make this site possible. We request you whitelist our site.